-
公开(公告)号:US20240299388A1
公开(公告)日:2024-09-12
申请号:US18572404
申请日:2022-06-23
申请人: Erasca, Inc.
发明人: Robert Field SHOEMAKER , Erin Denise LEW , Wei LIN , Leslie Harris BRAIL , Leenus MARTIN , Jingchuan ZHANG , Joanne OH
IPC分类号: A61K31/506 , A61K31/497 , A61K31/519 , A61K31/5383 , A61K39/395 , A61K45/06 , A61P35/00
CPC分类号: A61K31/506 , A61K31/497 , A61K31/519 , A61K31/5383 , A61K39/3955 , A61K45/06 , A61P35/00
摘要: The present disclosure relates generally to the use an ERK1/2 inhibitor in combination with a SHP2 inhibitor for treating cancer, specifically solid tumors.
-
公开(公告)号:US20240285625A1
公开(公告)日:2024-08-29
申请号:US18572399
申请日:2022-06-23
申请人: Erasca, Inc.
发明人: Robert Field SHOEMAKER , Erin Denise LEW , Wei LIN , Jingchuan ZHANG , Joanne OH
IPC分类号: A61K31/506 , A61K31/519 , A61K45/06 , A61P35/00
CPC分类号: A61K31/506 , A61K31/519 , A61K45/06 , A61P35/00
摘要: The present disclosure relates generally to the use of an ERK 1/2 inhibitor in combination with a KRAS G12C inhibitor for treating cancer, specifically solid tumors.
-
公开(公告)号:US20240285624A1
公开(公告)日:2024-08-29
申请号:US18570831
申请日:2022-06-23
申请人: Erasca, Inc.
发明人: Robert Field SHOEMAKER , Wei LIN , Erin Denise LEW , Jingchuan ZHANG , Joanne OH , Leenus MARTIN , Leslie Harris BRAIL
IPC分类号: A61K31/506 , A61K31/497
CPC分类号: A61K31/506 , A61K31/497
摘要: The present disclosure relates generally to the use of an ERK1/2 inhibitor or a SHP2 inhibitor in combination with a FLT3 inhibitor, such as gilteritinib, for treating cancer, specifically acute myeloid leukemia (AML).
-
公开(公告)号:US20240307392A1
公开(公告)日:2024-09-19
申请号:US18570830
申请日:2022-06-23
申请人: Erasca, Inc.
发明人: Robert Field SHOEMAKER , Erin Denise LEW , Wei LIN , Leslie Harris BRAIL , Leenus MARTIN , Jingchuan ZHANG , Joanne OH
IPC分类号: A61K31/506 , A61K31/497 , A61K31/519 , A61K39/395 , A61P35/00
CPC分类号: A61K31/506 , A61K31/497 , A61K31/519 , A61K39/3955 , A61P35/00
摘要: The present disclosure relates generally to the use of an ERK1/2 inhibitor in combination with a EGFR inhibitor for treating cancer, specifically solid tumors. The present disclosure also relates to the use of an ERK 1/2 inhibitor in combination with a EGFR inhibitor and a BRAF inhibitor for treating cancer, specifically solid tumors.
-
-
-